A new analysis from the PALOMA-2 study shows that subcutaneous administration of amivantamab every four weeks (Q4W), in ...

The anti-amyloid maintenance therapy offers a once-weekly, subcutaneous option after 18 months of intravenous treatment.

The US Food and Drug Administration (FDA) has approved the biologics license application for a subcutaneous formulation of ...

Topline results were announced from a phase 3 trial evaluating cemdisiran in adults with generalized myasthenia gravis (gMG).

The Alzheimer's Association welcomes today's U.S. Food and Drug Administration (FDA) action to approve weekly subcutaneous maintenance dosing of Leqembi® (lecanemab, Eisai/Biogen) for early ...

Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") announces today that ultra-long-acting subcutaneous (SQ) depot maintenance formulation of small molecule GLP-1 receptor (GLP-1R) agonist ASC30 ...

Leqembi IQLIK, a subcutaneous version of Leqembi, will launch on Oct. 6, 2025, with a list price of $375 per autoinjector.

The U.S. Food and Drug Administration has approved Leqembi Iqlik, a subcutaneous version of lecanemab, for weekly maintenance ...

FDA approves Leqembi Iqlik as a weekly subcutaneous injection for Alzheimer's treatment, enhancing patient convenience and ...

Aiming to deliver blockbuster sales of its Alzheimer’s-disease-fighting antibody Leqembi in its 2027 fiscal year, Eisai has cleared a key regulatory hurdle in its quest to grow the medicine's reach | ...

The once-weekly subcutaneous autoinjector picked up an FDA approval late last week that clears the way for it to be an ...

Biogen (NASDAQ:BIIB) and Eisai (OTCPK:ESAIY) announced the rolling submission of a marketing application to receive an FDA ...